logo
Reality check: Does apple cider vinegar have health benefits?

Reality check: Does apple cider vinegar have health benefits?

Globe and Mail19-05-2025

For centuries, apple cider vinegar has been used to treat a range of ills such as fever, coughs and colds.
Today, social media influencers and celebrities praise the tart, sour-tasting liquid for its ability to detox the body, lower blood sugar and cholesterol, banish bloating, burn body fat, get rid of acne and more.
Sounds too good to be true?
There is reason to be skeptical about many of apple cider vinegar's health claims.
For one or two, though, the evidence, while not robust, suggests it may be helpful. Here's what to know.
Apple cider vinegar (ACV) is made by fermenting crushed apples with yeast, which turn the sugars into alcohol.
A second fermentation then allows bacteria to convert the alcohol into acetic acid, the compound that gives vinegar its characteristic sour taste and smell.
Pasteurized apple cider vinegar is heat-treated to kill bacteria and extend shelf life. Unpasteurized apple cider vinegar is cloudy and contains the 'mother', a sediment of gut-healthy microbes.
Apple cider vinegar is available as a liquid, and also as tablet and gummy supplements; studies have focused on the liquid form.
Here's where the evidence stands on ACV's purported health and wellness benefits.
A 2025 review of clinical trials involving 463 adults with type 2 diabetes concluded that taking one to two tablespoons of ACV daily for at least eight weeks significantly reduced fasting blood glucose and hemoglobin A1c compared to placebo. (A hemoglobin A1c test measures your average blood sugar level over the previous three months.)
Two earlier meta-analyses of mostly low-quality clinical trials conducted in adults with overweight, obesity and/or Type 2 diabetes found that taking ACV daily for up to 12 weeks improved fasting glucose, hemoglobin A1c, total cholesterol and blood triglycerides. However, these beneficial effects were limited to participants with Type 2 diabetes.
There was no effect of ACV on LDL (bad) cholesterol levels in the bloodstream.
A clinical study from Iran involving 80 adults with Type 2 diabetes did find that, compared to the placebo treatment, taking two tablespoons of ACV daily for eight weeks significantly lowered LDL cholesterol.
Bottom line: ACV may lower blood glucose in people with Type 2 diabetes. It's unclear, though, whether it's beneficial for high blood cholesterol.
Acetic acid in ACV is thought to slow the rate that food empties from the stomach into the small intestine, causing a slower release and rise of glucose into the bloodstream. Acetic acid may also increase the body's ability to metabolize glucose and fats.
Studies investigating the impact of ACV on weight loss are few, small in size and of short duration.
A 2018 study found that taking one tablespoon of ACV twice daily for 12 weeks, while eating a calorie-restricted diet, reduced appetite and resulted in a modest weight loss compared to dieting alone.
It was unclear, though, whether eating fewer calories or taking apple cider vinegar influenced the findings.
A 2024 clinical study from Lebanon involving 120 participants, ages 12 to 25, who were overweight or living with obesity found that consuming one, two or three teaspoons of ACV daily for 12 weeks resulted in a significant reduction in body weight compared to placebo.
Measures of fasting blood glucose, cholesterol and triglycerides also improved in the ACV group.
Participants kept food diaries, but calorie and nutrient intakes weren't analyzed by the researchers. It's not known if participants changed the quantity or types of foods they ate during the study.
Consuming acetic acid with a meal may increase satiety, possibly helping you consume fewer calories during the day. Even so, ACV is not a magic bullet for weight loss.
There's no scientific evidence that ACV improves bloating, indigestion or acid reflux.
It's possible that consuming unpasteurized ACV, a natural source of probiotics, can benefit gut health by increasing the diversity and richness of the gut microbiome.
When it comes to clearing up acne, there's not enough reliable evidence to assess ACV's effectiveness. Ditto for using it topically to treat eczema or remove warts.
ACV is considered safe when consumed in food amounts.
It may, though, interact with some medications for diabetes and congestive heart failure, as well as certain diuretics. Consult your doctor before using ACV.
Don't drink ACV straight. Its high acidity can irritate your throat and esophagus, worsen acid reflux and damage tooth enamel.
Dilute one tablespoon of vinegar in eight ounces of water. Drink it before a meal once or twice a day. Or consume it as part of a meal in a vinaigrette salad dressing.
Acetic acid isn't unique to ACV. All vinegars contain it; balsamic, red wine, white wine and distilled white vinegar can be a substitute for apple cider vinegar.
Leslie Beck, a Toronto-based private practice dietitian, is director of food and nutrition at Medcan. Follow her on X @LeslieBeckRD

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Globe and Mail

time2 hours ago

  • Globe and Mail

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. 'Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,' said Paul Clancy, chair of the board of directors of Xilio Therapeutics. 'With over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde's extensive expertise as we advance toward the clinic with XTX501, our masked PD-1/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.' 'Xilio's innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,' said Dr. Bello. 'I am honored to join Xilio's board of directors at this important time and look forward to contributing to Xilio's efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.' Akintunde Bello, Ph.D. Dr. Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers and tumor-selective molecules. He most recently served as senior vice president, head of clinical pharmacology, pharmacometrics and bioanalysis at Bristol Myers Squibb Company (BMS) until his retirement in 2025. While at BMS, Dr. Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Prior to BMS, Dr. Bello spent more than a decade with Pfizer Inc. (Pfizer), where he was responsible for overseeing clinical pharmacology for Pfizer's late-stage oncology development programs. Dr. Bello received a in biomedical sciences from Portsmouth Polytechnic, an in instrumentation and analytical science from University of Manchester and a Ph.D. in pharmaceutical sciences from King's College, University of London. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding achievement of key milestones; and the potential benefits of any of Xilio's current or future product candidates in treating patients; and Xilio's strategy, goals, business plans and focus. The words 'aim,' 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'seek,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio's current or future product candidates; Xilio's ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio's advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio's product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio's ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio's ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio's business, including U.S. and China trade policies; Xilio's ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio's ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled 'Risk Factor Summary' and 'Risk Factors' in Xilio's filings with the U.S. Securities and Exchange Commission (SEC), including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Cohere launches AI health care agents in the U.S.
Cohere launches AI health care agents in the U.S.

Globe and Mail

time2 hours ago

  • Globe and Mail

Cohere launches AI health care agents in the U.S.

Canadian artificial intelligence company Cohere Inc. is entering the health care industry through a partnership with U.S.-based Ensemble Health Partners that uses AI agents to help hospitals and other providers manage their revenue. Cohere, founded in 2019, uses large-language models to build chatbots and generative-AI platforms for enterprise customers to automate some tasks. The partnership with Ensemble, launched Tuesday, uses a customized version of the North by Cohere platform that will run on health care providers' internal systems and help with tasks such as hospitals appealing insurance-claim denials and chasing down accounts receivable. The company said pre-launch tests of the tools accelerated denial appeals by 40 per cent and improved denial overturn rates by 15 per cent. Running on internal systems is a key part of how the AI system protects the safety of patients' information and complies with privacy law, said Cohere co-founder Ivan Zhang. 'There's no data leaving their system, because all the agents are in the house,' he said. Because of those privacy concerns, Mr. Zhang said the AI has to be trained on synthetic data, which would be similar to real-world data in likeness and structure but without any protected personal information. The foray into health-care follows Cohere's work in the financial sector, which has to adhere to similar privacy rules. In January, the company announced a partnership with Royal Bank of Canada to co-develop and run a customized platform called North for Banking which, among other things, helps employees answer questions from customers. Mr. Zhang said Cohere is focused on the U.S. market for now, but hopes to have more to announce for Canadian health-care soon. 'So far, we are focused on the U.S. markets. We want to take these learnings and adapt it to different systems in Canada and globally,' he said. Cohere did not disclose any financial terms or which U.S. clients are using the AI platform. The company also received a nod Tuesday from new federal AI minister Evan Solomon. In a speech in Ottawa, Mr. Solomon outlined the government's new approach to AI, saying it would shift from 'warnings and regulation' to celebrating industry 'champions' such as Cohere. Mr. Zhang said he was 'delighted' by the support and said there was a strong case to be made that investments in AI were part of strengthening Canada's economy and security. 'We've been very happy about the government's engagement so far,' he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store